Pfizer Inc. (NYSE:PFE) Shares Bought by Mystic Asset Management Inc.

Mystic Asset Management Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 185,136 shares of the biopharmaceutical company's stock after acquiring an additional 11,130 shares during the quarter. Pfizer comprises 1.2% of Mystic Asset Management Inc.'s investment portfolio, making the stock its 19th biggest holding. Mystic Asset Management Inc.'s holdings in Pfizer were worth $4,691,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after buying an additional 2,087 shares in the last quarter. Madison Investment Advisors LLC purchased a new stake in Pfizer during the fourth quarter worth about $5,360,000. Axxcess Wealth Management LLC boosted its holdings in Pfizer by 0.9% during the fourth quarter. Axxcess Wealth Management LLC now owns 194,907 shares of the biopharmaceutical company's stock worth $5,171,000 after buying an additional 1,696 shares in the last quarter. Finally, Horizon Investments LLC boosted its holdings in Pfizer by 1.6% during the fourth quarter. Horizon Investments LLC now owns 82,602 shares of the biopharmaceutical company's stock worth $2,156,000 after buying an additional 1,271 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 0.1%

NYSE:PFE traded down $0.02 during trading hours on Thursday, reaching $24.59. 47,333,190 shares of the company were exchanged, compared to its average volume of 41,955,789. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The firm has a market cap of $139.83 billion, a price-to-earnings ratio of 17.82, a PEG ratio of 0.90 and a beta of 0.58. The stock has a 50 day simple moving average of $23.99 and a 200 day simple moving average of $24.77. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period last year, the business posted $0.82 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.99%. Pfizer's payout ratio is 124.64%.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Bank of America boosted their price target on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Jefferies Financial Group boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. BMO Capital Markets decreased their price objective on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Finally, UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.